+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

BioNTech SE (BNTX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 61 Pages
  • September 2024
  • GlobalData
  • BioNTech SE
  • ID: 5819737
BioNTech SE (BNTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. The company's primary activities involve harnessing the immune system to address diseases with unmet medical needs, utilizing a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science, and artificial intelligence (AI) and machine learning (ML). BioNTech's product portfolio includes investigational mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules. Its first marketed product is Comirnaty. The company's products are designed to address the needs of cancer patients and combat infectious diseases. BioNTech collaborates with multiple global pharmaceutical companies, including Duality Biologics, Fosun Pharma, Genentech, Genevant, Genmab, OncoC4, Regeneron, and Pfizer. While the company operates globally, it aims to contribute to equitable access to medicine as part of its product strategy. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

BioNTech SE Key Recent Developments

  • Sep 05, 2024: BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
  • Aug 22, 2024: FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants
  • Jul 11, 2024: CureVac Provides Update on Hearing Dates in Patent Litigation Against Pfizer/BioNTech in Several Regions
  • May 31, 2024: Thousands of NHS Patients to Access Trials of Personalised Cancer ‘Vaccines’

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • BioNTech SE - Key Facts
  • BioNTech SE - Key Employees
  • BioNTech SE - Key Employee Biographies
  • BioNTech SE - Major Products and Services
  • BioNTech SE - History
  • BioNTech SE - Company Statement
  • BioNTech SE - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • BioNTech SE - Business Description
  • R&D Overview
  • BioNTech SE - Corporate Strategy
  • BioNTech SE - SWOT Analysis
  • SWOT Analysis - Overview
  • BioNTech SE - Strengths
  • BioNTech SE - Weaknesses
  • BioNTech SE - Opportunities
  • BioNTech SE - Threats
  • BioNTech SE - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • BioNTech SE, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • BioNTech SE, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • BioNTech SE, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 05, 2024: BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
  • Aug 22, 2024: FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants
  • Jul 11, 2024: CureVac Provides Update on Hearing Dates in Patent Litigation Against Pfizer/BioNTech in Several Regions
  • May 31, 2024: Thousands of NHS Patients to Access Trials of Personalised Cancer ‘Vaccines’
  • May 21, 2024: BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
  • May 07, 2024: BioNTech reports net loss of €315.1m in Q1 2024
  • Mar 20, 2024: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
  • Mar 20, 2024: BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
  • Mar 07, 2024: BioNTech Announces Planned Retirement of Sean Marett
  • Feb 09, 2024: MHRA approvals for Comirnaty (Pfizer/BioNTech) and Nuvaxovid (Novavax) COVID-19 vaccines
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • BioNTech SE, Key Facts
  • BioNTech SE, Key Employees
  • BioNTech SE, Key Employee Biographies
  • BioNTech SE, Major Products and Services
  • BioNTech SE, History
  • BioNTech SE, Subsidiaries
  • BioNTech SE, Key Competitors
  • BioNTech SE, Ratios based on current share price
  • BioNTech SE, Annual Ratios
  • BioNTech SE, Interim Ratios
  • BioNTech SE, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • BioNTech SE, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • BioNTech SE, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • BioNTech SE, Performance Chart (2019 - 2023)
  • BioNTech SE, Ratio Charts
  • BioNTech SE, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • BioNTech SE, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Immatics Biotechnologies GmbH
  • Curevac NV
  • Genmab AS
  • eTheRNA Immunotherapies NV
  • Deutsche Biotech Innovativ AG